Vi­a­tris and oth­ers be­come lat­est tar­gets of No­var­tis' En­tresto patent lit­i­ga­tion

No­var­tis pro­tects its block­busters like a bear and her cubs, re­cent­ly tak­ing a Gilenya patent bat­tle all the way to the Supreme Court. Now it’s fil­ing yet an­oth­er fed­er­al court com­plaint in an at­tempt to dri­ve off En­tresto gener­ics.

Vi­a­tris and My­lan are among No­var­tis’ lat­est tar­gets, as well as Alem­bic Phar­ma­ceu­ti­cals, Crys­tal Phar­ma­ceu­ti­cal, MSN Phar­ma­ceu­ti­cals and Nan­jing No­rat­e­ch Phar­ma­ceu­ti­cal. The com­pa­ny ar­gued in a new law­suit on Mon­day that ab­bre­vi­at­ed NDAs filed by the de­fen­dants for gener­ic ver­sions of 24 mg and 26 mg En­tresto tablets in­fringe on a patent dubbed ‘918 that ex­pires in No­vem­ber 2026.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER